Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Esophageal01
jRCT2031240571Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ifinatamab deruxtecan in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Started Mar 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031240571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240571.